Abstract: Telecommunication system comprises a terminal and a relay device which relays a communication path established on a network by the terminal, wherein the relay device sends certification information based on a demand of the terminal and the terminal checks whether the certification information is correct or not and the terminal establishes a communication path on the network when the certification information is correct.

Abstract: It is intended to provide methods for suppressing the huntingtin gene expression by using a double-stranded RNA (dsRNA), huntingtin gene expression inhibitors to suppress the huntingtin gene expression, and preventives and/or remedies of Huntington's disease. Targeting against a specific sequence of mRNA at immediately upstream of CAG repeats in HD genes of Huntington's disease, the huntingtin gene expression is suppressed by using a dsRNA homologous to the sequence. In this invention, a short siRNA (short double-stranded RNA) having bp as short as around 21-23 bp can be effectively used as the dsRNA homologous to a specific RNA sequence in a region at immediately upstream of CAG repeats. The dsRNA of this present invention can be used as a huntingtin gene expression inhibitor, or a preventive and/or a remedy of Huntington's disease by administering or introducing into a living body or a living cell in mammals for the prevention and/or treatment of Huntington's disease.

Abstract: The present invention provides an access control method of controlling acceptance or rejection of access to content from metadata. The access control method according to the present invention includes a step of producing metadata 3A for content 6A and embedding a digital signature 4A of a producer who has produced the metadata as producer information in the produced metadata 3A, a step of embedding an identifier 5A indicating which metadata are accessible to the content in license information required to play back the content 6A, and an access propriety control step of comparing the digital signature 4A with the identifier 5A to control propriety of access to the content 6A from the produced metadata 3A.

Abstract: The foam sheet of the present invention is biodegradable, can be recycled, has good processability, is lightweight, exhibits excellent appearance, has practically satisfactory heat resistance and is more acceptable to the environment. There is provided a crosslinked biodegradable resin continuous foam sheet comprising biodegradable resin, and has an expansion rate of about 1.5 to about 50 and a gel fraction of about 3% or more. There is further provided a method for producing the foam sheet comprising the steps of: (1) preparing a sheet from a resin composition comprising a biodegradable resin, a thermal decomposable blowing agent, and a crosslinking promoter; (2) irradiating the resulting sheet with an ionizing radiation to crosslink the resin composition; and (3) subjecting the crosslinked sheet to heat treatment to continuously prepare a crosslinked foam sheet.

Abstract: The present invention provides a manufacturing method of a high performance active matrix substrate at a high throughput with a less expensive apparatus, and an image display device using the active matrix substrate. On a stage moving in the short axis direction X and long axis direction Y on a rail, a glass substrate is carried, which has an amorphous silicon semiconductor film formed. Polycrystallized and large grain silicon film may be obtained by intensity modulating the pulsed laser beam in a line beam shape by means of a phase shift mask with a periodicity in the long axis direction Y of the laser beam, moving the laser beam randomly in the modulation direction of the amorphous silicon semiconductor film formed on the glass substrate to expose to crystallize the film. The image display device may incorporate an active matrix substrate having active elements such as thin film transistors formed by this silicon film.

Abstract: The present invention provides a manufacturing method of a high performance active matrix substrate at a high throughput with a less expensive apparatus, and an image display device using the active matrix substrate. On a stage moving in the short axis direction X and long axis direction Y on a rail, a glass substrate is carried, which has an amorphous silicon semiconductor film formed. Polycrystallized and large grain silicon film may be obtained by intensity modulating the pulsed laser beam in a line beam shape by means of a phase shift mask with a periodicity in the long axis direction Y of the laser beam, moving the laser beam randomly in the modulation direction of the amorphous silicon semiconductor film formed on the glass substrate to expose to crystallize the film. The image display device may incorporate an active matrix substrate having active elements such as thin film transistors formed by this silicon film.

Abstract: The foam sheet of the present invention is biodegradable, can be recycled, has good processability, is lightweight, exhibits excellent appearance, has practically satisfactory heat resistance and is more acceptable to the environment. There is provided a crosslinked biodegradable resin continuous foam sheet comprising biodegradable resin, and has an expansion rate of about 1.5 to about 50 and a gel fraction of about 3% or more. There is further provided a method for producing the foam sheet comprising the steps of: (1) preparing a sheet from a resin composition comprising a biodegradable resin, a thermal decomposable blowing agent, and a crosslinking promoter; (2) irradiating the resulting sheet with an ionizing radiation to crosslink the resin composition; and (3) subjecting the crosslinked sheet to heat treatment to continuously prepare a crosslinked foam sheet.

Abstract: The present invention provides a manufacturing method of a high performance active matrix substrate at a high throughput with a less expensive apparatus, and an image display device using the active matrix substrate. On a stage moving in the short axis direction X and long axis direction Y on a rail, a glass substrate is carried, which has an amorphous silicon semiconductor film formed. Polycrystallized and large grain silicon film may be obtained by intensity modulating the pulsed laser beam in a line beam shape by means of a phase shift mask with a periodicity in the long axis direction Y of the laser beam, moving the laser beam randomly in the modulation direction of the amorphous silicon semiconductor film formed on the glass substrate to expose to crystallize the film. The image display device may incorporate an active matrix substrate having active elements such as thin film transistors formed by this silicon film.

Abstract: The embodiment of the present invention provides a liquid crystal display element using cholesteric liquid crystals having a slight change in electrooptic properties even if the liquid crystals deteriorate by irradiation of light such as ultraviolet rays, etc., and a method for driving the same. An embodiment of the present invention further provides a liquid crystal display device in which pixel spaces are formed, in a matrix form, of a plurality of common electrodes and a plurality of segment electrodes, which are orthogonal to each other, and cholesteric liquid crystals and chiral nematic liquid crystals intervene in the pixel spaces.

Abstract: Object: To produce E-prostaglandins in a high yield and in a short time with suppressed formation of isomers.Structure: A process for preparing E-prostaglandins represented by the formula: ##STR1## (wherein A, R.sup.6 and R.sup.7 represent respectively an arbitrary group which does not participate in the reaction; B represents a vinylene or ethynylene group; and R.sup.4 and R.sup.5 may be the same or different from each other and each represents a hydrogen atom or a protective group of the hydroxyl group) which comprises reacting allyl esters of E-prostaglandins represented by the formula: ##STR2## (wherein R.sup.1 and R.sup.2 may be the same or different from each other and each represents a hydrogen atom or a lower alkyl group; R.sup.3 represents a hydrogen atom, a lower alkyl group, an alkenyl group or an aryl group; and A, B, R.sup.4, R.sup.5, R.sup.6 and R.sup.

Abstract: Object: To provide novel prostaglandin E.sub.1 analogues which have more excellent pharmaceutical effects, longer duration of the effects and less side-effects than the prior art prostaglandin E.sub.1 's.Constitution: A PGE.sub.1 analogue represented by the formula: ##STR1## (wherein A is a vinylene group or an ethynylene group, R.sup.1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an allyl group, R.sup.2 is a branched aliphatic hydrocarbon group having 5 to 10 carbon atoms), or a salt thereof.

Abstract: A prostaglandin derivative represented by the formula: ##STR1## wherein X is halogen atom R.sup.1 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and R.sup.2 is a cycloalkyl group having 3 to 10 carbon atoms, a cycloalkylmethyl group having 4 to 10 carbon atoms or a cycloalkylethyl group having 5 to 12 carbon atoms, or a salt thereof, which has an excellent lowering action of intraocular pressure and improving actions of renal diseases, ischemic heart diseases and heart failure.

Abstract: A prostaglandin E.sub.1 analogue represented by formula ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group; and X is an oxygen atom and R.sup.2 represents ##STR2## or X is a sulfur atom and R.sup.2 represents ##STR3## The compound has a strong and prolonged inhibitory action for platelet aggregation and is useful for treatment of various thrombotic diseases including peripheral circulatory disturbance.

Abstract: A prostaglandin derivative represented by formula ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, and R.sup.2 represents a cyclohexyl group or a cyclopentylmethyl group. This compound has physiological activities such as platelet aggregation-inhibiting action, renal blood vessel and coronary blood vessel-dilating actions and the like, and is useful for treatment of renal failure and diseases of circulatory organs.

Abstract: ObjectNovel PG derivatives having an excellent platelet aggregation inhibition activity are provided.ConstructionProstaglandin derivatives represented by formula: ##STR1## and salts thereof.

Abstract: Object: To provide novel prostaglandin E.sub.1 analogues which have more excellent pharmaceutical effects, longer duration of the effects and less side-effects than the prior art prostaglandin E.sub.1 's.Constitution: A PGE.sub.1 analogue represented by the formula: ##STR1## (wherein R.sup.1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an allyl group, and R.sup.2 is an alkyl group having 3 to 6 carbon atoms, an alkenyl group having 3 to 6 carbon atoms), or a salt thereof.

Abstract: A sulfonamide derivative represented by the Formula: ##STR1## wherein A, B, X, Y, R, m and n are as defined in the specification, and a salt thereof have thromboxane A.sub.2 antagonism, therefore they are useful, for example, as blood platelet aggregation inhibiting agents.

Abstract: A triazole derivative represented by the formula ##STR1## wherein R.sup.1 is a hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms, an acetyl group, a naphthylmethyl group, an anthrylmethyl group or a group of the formula ##STR2## wherein X, Y and Z are the same or different and each a hydrogen atom, a halogen atom, a lower alkyl group having 1 to 4 carbon atoms, a lower alkoxy group having 1 to 4 carbon atoms, a hydroxyl group, a nitro group, a trifluoromethyl group, a cyano group or a benzyloxy group, and R.sup.2 is a hydrogen atom or an acetyl group, and R.sup.3 is a hydrogen atom, an acetyl group or a group of the formula ##STR3## wherein R.sup.1 and R.sup.2 are as defined above, are useful as the inhibitors of lipid peroxidation.